Milrinone: A Clinical Trial in 29 Dogs With Moderate to Severe Congestive Heart Failure

D. Mark Keister, Mark D Kittleson, John D. Bonagura, Frank S. Pipers, Kenneth W. Knauer

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Milrinone, a positive inotropic drug with vasodilating properties, was administered at doses of 0.5 to 1 mg/kg orally twice daily to 29 dogs with moderateto severe congestive heart failure (CHF). Significant echocardiographic improvement in ventricular systolic function was observed after 3 days of administration of milrinone and at the patients' last echocardiographic observation (day 21in 25 subjects, day 7 in 2 subjects, and day 3 in 2 subjects). Echocardiographic shortening fraction at the initial measurement had a median increase of 6.14%(P < 0.001), and for the last observation a 2.83% increase (P < 0.005). Most patients also showed improvement in their clinical signs as assessed by the veterinarian (72%) and by owner's evaluation (81%). No consistent problem or adverse reaction to milrinone was observed, except for a small number ofclinically manageable ventricular dysrhythmias. Milrinone appears in this trialto be effective for the treatment of advanced CHF in dogs.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalJournal of Veterinary Internal Medicine
Issue number2
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • veterinary(all)


Dive into the research topics of 'Milrinone: A Clinical Trial in 29 Dogs With Moderate to Severe Congestive Heart Failure'. Together they form a unique fingerprint.

Cite this